trial · primary record
Orelabrutinib
Secondary Progressive Multiple Sclerosis
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 990 |
| Primary completion | 2030-07 |
| Primary endpoint | Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks |
| Registry ID | NCT07299019 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:15.204Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07299019
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.